Wu Yijun, Han Chang, Wang Zhile, Gong Liang, Liu Jianghao, Chong Yuming, Liu Xinyu, Liang Naixin, Li Shanqing
Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Peking Union Medical College, Eight-year MD Program, Chinese Academy of Medical Sciences, Beijing, China.
Front Oncol. 2020 Aug 7;10:1322. doi: 10.3389/fonc.2020.01322. eCollection 2020.
Lymph node metastasis (LNM) status is of key importance for the decision-making on treatment and survival prediction. There is no reliable method to precisely evaluate the risk of LNM in NSCLC patients. This study aims to develop and validate a dynamic nomogram to evaluate the risk of LNM in small-size NSCLC. The NSCLC ≤ 2 cm patients who underwent initial pulmonary surgery were retrospectively reviewed and randomly divided into a training cohort and a validation cohort as a ratio of 7:3. The training cohort was used for the least absolute shrinkage and selection operator (LASSO) regression to select optimal variables. Based on variables selected, the logistic regression models were developed, and were compared by areas under the receiver operating characteristic curve (AUCs) and decision curve analysis (DCA). The optimal model was used to plot a dynamic nomogram for calculating the risk of LNM and was internally and externally well-validated by calibration curves. LNM was observed in 12.0% (83/774) of the training cohort and 10.1% (33/328) of the validation cohort ( = 0.743). The optimal model was used to plot a nomogram with six variables incorporated, including tumor size, carcinoembryonic antigen, imaging density, pathological type (adenocarcinoma or non-adenocarcinoma), lymphovascular invasion, and pleural invasion. The nomogram model showed excellent discrimination (AUC = 0.895 vs. 0.931) and great calibration in both the training and validation cohorts. At the threshold probability of 0-0.8, our nomogram adds more net benefits than the treat-none and treat-all lines in the decision curve. This study firstly developed a cost-efficient dynamic nomogram to precisely and expediently evaluate the risk of LNM in small-size NSCLC and would be helpful for clinicians in decision-making.
淋巴结转移(LNM)状态对于治疗决策和生存预测至关重要。目前尚无可靠方法精确评估非小细胞肺癌(NSCLC)患者的LNM风险。本研究旨在开发并验证一种动态列线图,以评估小尺寸NSCLC患者的LNM风险。对接受初次肺手术的≤2 cm NSCLC患者进行回顾性分析,并按7:3的比例随机分为训练队列和验证队列。训练队列用于通过最小绝对收缩和选择算子(LASSO)回归选择最佳变量。基于所选变量,构建逻辑回归模型,并通过受试者操作特征曲线下面积(AUC)和决策曲线分析(DCA)进行比较。使用最佳模型绘制动态列线图以计算LNM风险,并通过校准曲线进行内部和外部验证。训练队列中12.0%(83/774)的患者出现LNM,验证队列中10.1%(33/328)的患者出现LNM(P = 0.743)。使用最佳模型绘制包含六个变量的列线图,这六个变量包括肿瘤大小、癌胚抗原、影像密度、病理类型(腺癌或非腺癌)、淋巴管侵犯和胸膜侵犯。列线图模型在训练队列和验证队列中均显示出良好的区分度(AUC分别为0.895和0.931)和出色的校准度。在阈值概率为0 - 0.8时,我们的列线图在决策曲线中比不治疗和全部治疗线增加了更多的净效益。本研究首次开发了一种经济高效的动态列线图,可精确、便捷地评估小尺寸NSCLC患者的LNM风险,有助于临床医生进行决策。